The global medical oxygen systems market was valued at USD 12.35 billion in 2025. The market is estimated at USD 13.10 billion in 2026 and is projected to reach USD 24.36 billion by 2036, at a CAGR of 6.4% during the forecast period 2026-2036. This report provides a detailed assessment of the market, covering oxygen access policy, clinical demand, generation and distribution technologies, standards, procurement and pricing, the supplier landscape, and growth opportunities.
The market includes the equipment, systems, and related services used to generate, store, pipe, and deliver medical oxygen in hospitals, pre-hospital care, and the home. This covers PSA and VPSA plants, concentrators, cryogenic tanks, and cylinder manifolds; pipework, terminal units, and alarm panels; cannulae, masks, high-flow systems, and conserving devices; and installation, verification, maintenance, and home oxygen services. Ventilators, anesthesia machines, hyperbaric chambers, other medical gas systems, and sales of the oxygen itself are excluded.
According to the Lancet Global Health Commission on medical oxygen security, over 5 billion people, more than 60% of the global population, cannot obtain safe and affordable medical oxygen, and closing the gaps would cost USD 6.8 billion a year through 2030. According to the Global Oxygen Alliance, maintaining and running systems already installed needs about USD 8.2 billion, so sustaining existing capacity now costs more than expanding it. World Health Assembly resolution WHA76.3 of May 2023 requires progress reports to the Health Assembly in 2026, 2028, and 2030, yet fewer than 30 countries have robust national oxygen plans.
Pandemic-era purchases pulled demand forward, as the ACT-Accelerator Oxygen Emergency Taskforce delivered 879 PSA plants and about 225,920 concentrators in 2021-2023, much of which is not yet due for replacement. In the U.S., Medicare pays home oxygen as one bundled monthly amount and ends equipment payments after 36 months, while weak power supply limits on-site generation and pipeline upgrades in occupied hospitals are costly and often deferred. Keeping systems working is the central challenge: a 2022 assessment in Nigeria found 24% of 5,741 concentrators non-functional, and the Lancet Commission reported stockouts or interruptions at 93% of primary care facilities in low- and middle-income countries. Engineer shortages, quality duties for site-generated oxygen, and cylinder logistics add pressure.
Multilateral funding is the main near-term opportunity, with the Global Fund reporting USD 564 million invested in medical oxygen across 83 countries, and according to Unitaid, its USD 22 million commitment will fund four liquid oxygen plants in Kenya and Tanzania adding more than 60 tons per day. Managed oxygen contracts that shift uptime and spare parts to the supplier, along with solar-powered off-grid generation, also offer growth. Key trends include the wider acceptance of oxygen 93 percent for pipeline supply under the fourth edition of ISO 7396-1, refreshed ISO equipment standards, pipeline telemetry, consolidation among consumable suppliers, and local manufacturing in Africa and Asia.
By offering, the medical oxygen systems market is segmented into oxygen source & generation systems, medical gas pipeline & distribution systems, oxygen therapy delivery devices & consumables, and services. Oxygen source & generation systems are expected to account for the largest share in 2026, as plants, cryogenic storage, and concentrator fleets carry high capital value and donor programs have installed them in large numbers. Services are expected to grow at the highest CAGR, supported by the high cost of keeping installed systems running, verification duties under the 2026 edition of Health Technical Memorandum (HTM) 02-01 and the ASSE/IAPMO/ANSI Series 6000-2024 standard, and the move toward managed oxygen contracts. Within delivery devices, high-flow nasal oxygen systems gain from European Respiratory Society guidance favoring the therapy in acute hypoxemic respiratory failure.
By technology, the medical oxygen systems market is segmented into pressure swing adsorption, vacuum pressure swing adsorption, cryogenic air separation supply, membrane separation, and emerging oxygen generation technologies. Pressure swing adsorption is expected to hold the largest share in 2026, as it runs both hospital plants and most stationary and portable concentrators, and WHO plant specifications are built around it. Vacuum pressure swing adsorption is expected to post the highest CAGR, since better recovery and lower power use at large capacities make it competitive with delivered liquid oxygen in bigger hospitals. Cryogenic air separation remains the basis of bulk liquid supply, now extending into East Africa through new regional plants.
By oxygen grade, the medical oxygen systems market is segmented into pharmacopoeial oxygen 99.5 percent and above, oxygen 93 percent, and non-pharmacopoeial & below-monograph oxygen. Pharmacopoeial oxygen 99.5 percent and above is expected to hold the largest share in 2026, reflecting the established role of liquid and cylinder supply in high-income health systems and the European Pharmacopoeia standard for cryogenic oxygen. Oxygen 93 percent is expected to grow the fastest, as ISO 7396-1 now covers pipelines fed only by such sources, the U.S. Pharmacopeia defines the product, and WHO estimates put concentrator oxygen well below cylinder oxygen in cost. The below-monograph category covers oxygen that does not meet these pharmacopoeial specifications.
By installation type, the medical oxygen systems market is segmented into centralized pipeline-fed systems, decentralized point-of-care systems, and mobile & containerized systems. Centralized pipeline-fed systems are expected to hold the largest share in 2026, because HTM 02-01 and ISO 7396-1 require three supply sources for each gas and larger hospitals need dense terminal unit networks. Decentralized point-of-care systems are expected to grow at the highest CAGR, as the Lancet Commission found oxygen in only a small minority of primary care facilities, making bedside concentrators the practical route to coverage. Mobile and containerized systems serve sites that need oxygen without a permanent plant.
By application, the medical oxygen systems market is segmented into respiratory care, critical & intensive care, surgery & anesthesia support, neonatal & pediatric care, maternal & obstetric care, emergency, trauma & pre-hospital care, and home & long-term oxygen therapy. Respiratory care is expected to hold the largest share in 2026, given the oxygen needs of chronic obstructive pulmonary disease, which WHO ranks as the third leading cause of death. Neonatal & pediatric care is expected to grow the fastest, driven by childhood pneumonia, oxygen's place in WHO and UNICEF treatment guidance, and the Lancet Commission's call for oxygen and pulse oximetry wherever newborns are treated. Critical care also matters, as high-flow therapy raises per-bed flow in high-dependency units.
By end user, the medical oxygen systems market is segmented into hospitals, ambulatory care settings, long-term care & nursing facilities, home care settings, emergency medical services & air ambulance operators, and military, humanitarian & field facilities. Hospitals are expected to hold the largest share in 2026, as pipelines, generation plants, and high-flow capacity sit mainly in inpatient facilities, and Air Liquide alone serves about 20,000 hospitals and clinics. Home care settings are expected to grow at the highest CAGR, supported by rising home respiratory prescriptions, the 2.3 million home patients Air Liquide supports, and large regional contracts such as its Valencia award. Emergency and field users often work where piped oxygen is unavailable, so cylinder logistics shape buying.
North America is set to hold the largest share of the medical oxygen systems market in 2026, supported by dense pipeline infrastructure built to NFPA 99, a large home oxygen base, and high contract prices for equipment and services. In the U.S., Medicare spent about USD 9.0 billion on durable medical equipment, prosthetics, orthotics, and supplies in 2025. Linde placed its U.S. homecare business, Lincare, under strategic review in July 2026, citing labor costs and reimbursement changes.
Asia-Pacific is expected to grow at the highest CAGR, reflecting large unmet need and a strong manufacturing base. The Lancet Commission found that only 22% of acute oxygen need is met in South Asia and only 26% across East Asia and the Pacific. India approved 551 PSA plants in principle under the PM CARES Fund in 2021 and has a sizable cryogenic equipment industry. Europe holds a significant share, backed by EU medical device rules for pipelines and the reissued U.K. HTM 02-01. Latin America, anchored by Brazil, faces a narrower coverage gap than Asia or Africa, while the Middle East & Africa pairs Gulf hospital construction with the widest gap in sub-Saharan Africa.
The medical oxygen systems market is moderately fragmented, with industrial gas groups, pipeline and plant specialists, cryogenic and cylinder makers, concentrator manufacturers, consumable suppliers, and home care providers competing on standards compliance, quality assurance, delivered cost, uptime, service reach, and the ability to carry long-term operating contracts. Recent activity includes Baker Hughes' completed acquisition of Chart Industries in July 2026, Nippon Sanso Holdings' purchase of Esteve Teijin Healthcare, SOL Group's acquisition of VitalAire Schweiz, and Air Liquide's home respiratory contracts in Madrid and Valencia.
Key companies profiled in the report include Linde plc (U.K.), Air Liquide S.A. (France), Air Products and Chemicals, Inc. (U.S.), Messer SE & Co. KGaA (Germany), Nippon Sanso Holdings Corporation (Japan), Atlas Copco AB (Sweden), Koninklijke Philips N.V. (Netherlands), ResMed Inc. (U.S.), Invacare Holdings Corporation (U.S.), Inogen, Inc. (U.S.), Drägerwerk AG & Co. KGaA (Germany), GCE Group AB (Sweden), Beacon Medaes (Atlas Copco) (U.S.), Oxair Gas Systems (Australia), Novair SAS (France), OGSI (Oxygen Generating Systems Intl.) (U.S.), and Chart Industries, Inc. (U.S.).
The market includes the equipment, systems, and related services used to generate, store, pipe, and deliver medical oxygen in hospitals, pre-hospital care, and the home. This covers PSA and VPSA plants, concentrators, cryogenic tanks, and cylinder manifolds; pipework, terminal units, and alarm panels; cannulae, masks, high-flow systems, and conserving devices; and installation, verification, maintenance, and home oxygen services. Ventilators, anesthesia machines, hyperbaric chambers, other medical gas systems, and sales of the oxygen itself are excluded.
According to the Lancet Global Health Commission on medical oxygen security, over 5 billion people, more than 60% of the global population, cannot obtain safe and affordable medical oxygen, and closing the gaps would cost USD 6.8 billion a year through 2030. According to the Global Oxygen Alliance, maintaining and running systems already installed needs about USD 8.2 billion, so sustaining existing capacity now costs more than expanding it. World Health Assembly resolution WHA76.3 of May 2023 requires progress reports to the Health Assembly in 2026, 2028, and 2030, yet fewer than 30 countries have robust national oxygen plans.
Market Dynamics
Demand in the medical oxygen systems market is led by national and donor efforts to close the coverage gap, which are turning into orders for plants, liquid storage, pipelines, and delivery devices, while WHA76.3 pushes governments to prepare costed oxygen plans and build medical gas systems into new facilities. Clinical need is large, as the World Health Organization (WHO) links about 3.4 million deaths in 2023 to chronic obstructive pulmonary disease, and pneumonia killed 740,180 children under five in 2019. High-flow nasal oxygen needs far more flow per bed than CPAP or ventilation, and Fisher & Paykel Healthcare reported Hospital revenue up 18% for the year to March 2026. Expanding home and long-term oxygen therapy adds steady demand for concentrators and conserving devices.Pandemic-era purchases pulled demand forward, as the ACT-Accelerator Oxygen Emergency Taskforce delivered 879 PSA plants and about 225,920 concentrators in 2021-2023, much of which is not yet due for replacement. In the U.S., Medicare pays home oxygen as one bundled monthly amount and ends equipment payments after 36 months, while weak power supply limits on-site generation and pipeline upgrades in occupied hospitals are costly and often deferred. Keeping systems working is the central challenge: a 2022 assessment in Nigeria found 24% of 5,741 concentrators non-functional, and the Lancet Commission reported stockouts or interruptions at 93% of primary care facilities in low- and middle-income countries. Engineer shortages, quality duties for site-generated oxygen, and cylinder logistics add pressure.
Multilateral funding is the main near-term opportunity, with the Global Fund reporting USD 564 million invested in medical oxygen across 83 countries, and according to Unitaid, its USD 22 million commitment will fund four liquid oxygen plants in Kenya and Tanzania adding more than 60 tons per day. Managed oxygen contracts that shift uptime and spare parts to the supplier, along with solar-powered off-grid generation, also offer growth. Key trends include the wider acceptance of oxygen 93 percent for pipeline supply under the fourth edition of ISO 7396-1, refreshed ISO equipment standards, pipeline telemetry, consolidation among consumable suppliers, and local manufacturing in Africa and Asia.
Segment Analysis
The report analyzes the market by offering, technology, oxygen grade, installation type, application, end user, and geography, helping stakeholders identify the most attractive areas for investment, product development, and service growth.By offering, the medical oxygen systems market is segmented into oxygen source & generation systems, medical gas pipeline & distribution systems, oxygen therapy delivery devices & consumables, and services. Oxygen source & generation systems are expected to account for the largest share in 2026, as plants, cryogenic storage, and concentrator fleets carry high capital value and donor programs have installed them in large numbers. Services are expected to grow at the highest CAGR, supported by the high cost of keeping installed systems running, verification duties under the 2026 edition of Health Technical Memorandum (HTM) 02-01 and the ASSE/IAPMO/ANSI Series 6000-2024 standard, and the move toward managed oxygen contracts. Within delivery devices, high-flow nasal oxygen systems gain from European Respiratory Society guidance favoring the therapy in acute hypoxemic respiratory failure.
By technology, the medical oxygen systems market is segmented into pressure swing adsorption, vacuum pressure swing adsorption, cryogenic air separation supply, membrane separation, and emerging oxygen generation technologies. Pressure swing adsorption is expected to hold the largest share in 2026, as it runs both hospital plants and most stationary and portable concentrators, and WHO plant specifications are built around it. Vacuum pressure swing adsorption is expected to post the highest CAGR, since better recovery and lower power use at large capacities make it competitive with delivered liquid oxygen in bigger hospitals. Cryogenic air separation remains the basis of bulk liquid supply, now extending into East Africa through new regional plants.
By oxygen grade, the medical oxygen systems market is segmented into pharmacopoeial oxygen 99.5 percent and above, oxygen 93 percent, and non-pharmacopoeial & below-monograph oxygen. Pharmacopoeial oxygen 99.5 percent and above is expected to hold the largest share in 2026, reflecting the established role of liquid and cylinder supply in high-income health systems and the European Pharmacopoeia standard for cryogenic oxygen. Oxygen 93 percent is expected to grow the fastest, as ISO 7396-1 now covers pipelines fed only by such sources, the U.S. Pharmacopeia defines the product, and WHO estimates put concentrator oxygen well below cylinder oxygen in cost. The below-monograph category covers oxygen that does not meet these pharmacopoeial specifications.
By installation type, the medical oxygen systems market is segmented into centralized pipeline-fed systems, decentralized point-of-care systems, and mobile & containerized systems. Centralized pipeline-fed systems are expected to hold the largest share in 2026, because HTM 02-01 and ISO 7396-1 require three supply sources for each gas and larger hospitals need dense terminal unit networks. Decentralized point-of-care systems are expected to grow at the highest CAGR, as the Lancet Commission found oxygen in only a small minority of primary care facilities, making bedside concentrators the practical route to coverage. Mobile and containerized systems serve sites that need oxygen without a permanent plant.
By application, the medical oxygen systems market is segmented into respiratory care, critical & intensive care, surgery & anesthesia support, neonatal & pediatric care, maternal & obstetric care, emergency, trauma & pre-hospital care, and home & long-term oxygen therapy. Respiratory care is expected to hold the largest share in 2026, given the oxygen needs of chronic obstructive pulmonary disease, which WHO ranks as the third leading cause of death. Neonatal & pediatric care is expected to grow the fastest, driven by childhood pneumonia, oxygen's place in WHO and UNICEF treatment guidance, and the Lancet Commission's call for oxygen and pulse oximetry wherever newborns are treated. Critical care also matters, as high-flow therapy raises per-bed flow in high-dependency units.
By end user, the medical oxygen systems market is segmented into hospitals, ambulatory care settings, long-term care & nursing facilities, home care settings, emergency medical services & air ambulance operators, and military, humanitarian & field facilities. Hospitals are expected to hold the largest share in 2026, as pipelines, generation plants, and high-flow capacity sit mainly in inpatient facilities, and Air Liquide alone serves about 20,000 hospitals and clinics. Home care settings are expected to grow at the highest CAGR, supported by rising home respiratory prescriptions, the 2.3 million home patients Air Liquide supports, and large regional contracts such as its Valencia award. Emergency and field users often work where piped oxygen is unavailable, so cylinder logistics shape buying.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, spanning 19 country-level markets (with Australia & New Zealand assessed together) and four rest-of-region groups. The regional analysis considers coverage gaps, hospital infrastructure, reimbursement, regulation, donor funding, and local manufacturing.North America is set to hold the largest share of the medical oxygen systems market in 2026, supported by dense pipeline infrastructure built to NFPA 99, a large home oxygen base, and high contract prices for equipment and services. In the U.S., Medicare spent about USD 9.0 billion on durable medical equipment, prosthetics, orthotics, and supplies in 2025. Linde placed its U.S. homecare business, Lincare, under strategic review in July 2026, citing labor costs and reimbursement changes.
Asia-Pacific is expected to grow at the highest CAGR, reflecting large unmet need and a strong manufacturing base. The Lancet Commission found that only 22% of acute oxygen need is met in South Asia and only 26% across East Asia and the Pacific. India approved 551 PSA plants in principle under the PM CARES Fund in 2021 and has a sizable cryogenic equipment industry. Europe holds a significant share, backed by EU medical device rules for pipelines and the reissued U.K. HTM 02-01. Latin America, anchored by Brazil, faces a narrower coverage gap than Asia or Africa, while the Middle East & Africa pairs Gulf hospital construction with the widest gap in sub-Saharan Africa.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard, and market share/rank analysis by key player for 2025, together with company profiles covering business overviews, financial performance, product portfolios, strategic developments, and SWOT analyses.The medical oxygen systems market is moderately fragmented, with industrial gas groups, pipeline and plant specialists, cryogenic and cylinder makers, concentrator manufacturers, consumable suppliers, and home care providers competing on standards compliance, quality assurance, delivered cost, uptime, service reach, and the ability to carry long-term operating contracts. Recent activity includes Baker Hughes' completed acquisition of Chart Industries in July 2026, Nippon Sanso Holdings' purchase of Esteve Teijin Healthcare, SOL Group's acquisition of VitalAire Schweiz, and Air Liquide's home respiratory contracts in Madrid and Valencia.
Key companies profiled in the report include Linde plc (U.K.), Air Liquide S.A. (France), Air Products and Chemicals, Inc. (U.S.), Messer SE & Co. KGaA (Germany), Nippon Sanso Holdings Corporation (Japan), Atlas Copco AB (Sweden), Koninklijke Philips N.V. (Netherlands), ResMed Inc. (U.S.), Invacare Holdings Corporation (U.S.), Inogen, Inc. (U.S.), Drägerwerk AG & Co. KGaA (Germany), GCE Group AB (Sweden), Beacon Medaes (Atlas Copco) (U.S.), Oxair Gas Systems (Australia), Novair SAS (France), OGSI (Oxygen Generating Systems Intl.) (U.S.), and Chart Industries, Inc. (U.S.).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global medical oxygen systems market.
- Explains how coverage-gap funding, WHA76.3, respiratory disease, high-flow therapy, and home oxygen growth shape demand.
- Assesses the impact of post-pandemic demand, home oxygen reimbursement, power reliability, and pipeline upgrade costs.
- Identifies high-growth opportunities across offering, technology, oxygen grade, installation type, application, end user, and region.
- Tracks changes in pipeline and device standards, including ISO 7396-1 and HTM 02-01.
- Benchmarks leading companies on offerings, service networks, acquisitions, and contracts.
- Supports product planning, tender strategy, and market entry decisions for equipment makers, gas suppliers, and investors.
Key Questions Answered
- How big is the global medical oxygen systems market today, and how will it grow through 2036?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How will donor funding and national oxygen plans under WHA76.3 affect equipment and service demand?
- How does the acceptance of oxygen 93 percent for pipeline supply change the outlook for on-site generation?
- Why is sustaining installed capacity becoming as important as new installations?
- Which offering, technology, oxygen grade, installation type, application, and end-user segments will grow the fastest?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading companies in the market, and how do they compete?
- What acquisitions, contracts, and investments are shaping the competitive landscape?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. Medical Oxygen Systems Market, by Offering
6. Medical Oxygen Systems Market, by Technology
7. Medical Oxygen Systems Market, by Oxygen Grade
8. Medical Oxygen Systems Market, by Installation Type
9. Medical Oxygen Systems Market, by Application
10. Medical Oxygen Systems Market, by End User
11. Medical Oxygen Systems Market, by Geography
12. Competitive Landscape
13. Company Profiles
14. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Linde plc
- Air Liquide S.A.
- Air Products and Chemicals, Inc.
- Messer SE & Co. KGaA
- Nippon Sanso Holdings Corporation
- Atlas Copco AB
- Koninklijke Philips N.V.
- ResMed Inc.
- Invacare Holdings Corporation
- Inogen, Inc.
- Drägerwerk AG & Co. KGaA
- GCE Group AB
- Beacon Medaes
- Oxair Gas Systems
- Novair SAS
- OGSI
- Chart Industries, Inc.
